Patient population for the NAVIGATE trial is based on non-invasive tests and clinical criteria utilizing latest treatment guidelines for portal ...

Liver disease, which is treatable when discovered early, often goes undetected until late stages, but a new study revealed ...

Since the adoption of a new model for assessing the severity of liver disease, women are more likely to be added to the ...

An AI program trained to spot a leading type of the disease, called metabolic-associated steatotic liver disease (MASLD), ...

INTEGRIS-PSC featured in an oral late breaker presentationSOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, ...

Since the adoption of a new model for assessing the severity of liver disease, women are more likely to be added to the ...

The research found beer consumers have lower-quality diets, are less active and are more likely to smoke cigarettes compared ...

Liver disease, which is treatable when discovered early, often goes undetected until late stages, but a new study revealed ...

Salix Pharmaceuticals ("Salix"), today announced the first look at its late-stage RED-C clinical trial program which will be presented at the American Association for the Study of Liver Disease (AASLD ...

Given the increasing prevalence and mortality rates, targeted strategies are needed to reduce this growing health burden in ...

Artificial Intelligence (AI) can accurately detect early-stage metabolic-associated steatotic liver disease (MASLD) by using ...